medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

A Systematic Review on the Effect of Diabetes Mellitus on the Pharmacokinetics of Tuberculosis Drugs

Authors: Muge Cevik[1*] , Ann Sturdy[2], Alberto Enrico Maraolo[3] ,Bart G.J. Dekkers[4], Onno W. Akkerman[5,6,], Stephen H. Gillespie[1], Jan Willem C. Alffenaar[7-9]

Affiliations:

1. Division of Infection and Global Health Research, School of Medicine, University of St Andrews, UK
2. Department of Infectious Disease, Faculty of Medicine, Imperial College London, UK
3. Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples 'Federico II', Italy
4. University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands
5. University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands
6. University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, the Netherlands
7. The University of Sydney Institute for Infectious Diseases, Sydney, NSW, Australia.
8. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
9. Westmead Hospital, Westmead, NSW, Australia

Runninng head : Pharmacokinetics of TB Drugs in DM

***Corresponding author:**

Dr Muge Cevik

Division of Infection and Global Health Research,

School of Medicine, University of St Andrews, Fife, KY16 9TF

Telephone number: +447732800814

Email address: mc349@st-andrews.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Objectives

The coexistence of TB and DM (TB-DM) has been associated with an increased risk of treatment failure, death, delayed culture conversion and drug resistance. As plasma concentrations may influence clinical outcomes, we evaluated the evidence on the PK of TB drugs in DM individuals to guide management.

Methods

We performed a systematic review and meta-analysis through searches of major databases from 1946 to 6 July 2023. PROSPERO (CRD42022323566).

Results

Out of 4173 potentially relevant articles, we identified 16 studies assessing rifampicin PK, 9 on isoniazid, 8 on pyrazinamide and 3 on ethambutol. Two studies reported on second line anti-TB drugs. According to our analysis, RIF Tmax was significantly prolonged in patients with DM compared to non-DM patients. We found no significant differences for RIF C_{max}, AUC $_{0\text{-}24}$ or C2hr, INH C2hr, PZA C2hr, PZA T_{max} and ETB T_{max}. While RIF C2hr was slightly reduced in TB-DM patients, this finding was not statistically significant.

Conclusions

This review comprehensively examines the impact of DM on the PK of TB drugs. We observed significant heterogeneity among studies. Given the association between lower plasma concentrations and poor clinical outcomes among DM patients, we recommend a higher dose limit to correct for larger bodyweight of patients with DM.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION

The global tuberculosis (TB) burden remains substantial, with more than 10 million people newly diagnosed per year. [1] Non-communicable diseases continue to pose challenges for both the management of TB and control strategies. For instance, over the next 10 years, the prevalence of Diabetes mellitus (DM) is estimated to double globally, with TB and DM co-epidemic surpassing the TB-HIV coinfection in low-middle income countries. [2,3] More alarmingly DM is increasing in the same population that is at high risk for developing TB.

DM is specifically important for the TB epidemic and future policies as DM has been shown to double the risk of acquiring TB [4,5] and DM patients have three-fold increased risk of progression to active disease, [5] highlighting that increased prevelance of DM will help to maintain the TB epidemic. In addition, TB-DM patients experience increased risk of severe disease, treatment failure, relapse and increased risk of death [6,7] as well as delayed sputum culture conversion and a greater risk of developing drug resistance. [8,9]

There is however limited practical evidence to underpin treatment guidelines for TB-DM patients, such as length of treatment and drug dosing. This is important as plasma concentrations of TB medications may affect the clinical outcome. Zheng et al [10] showed an association between plasma concentrations of first line anti-TB drugs, culture conversion and clinical outcomes. Alfarisi et al. [11] demonstrated a positive association between time to culture conversion and isoniazid (INH) and rifampicin (RIF) concentrations and negative association with pyrazinamide (PZA) levels in DM patients. Pharmacokinetics (PK) of many other drugs are known to be altered in diabetic individuals. [12] DM may affect kidney function, gastric emptying and drug metabolism pathways. [12] This highlights the importance of understanding PK in TB-DM population. [13]

In this systematic review and meta-analysis, we evaluated the available evidence on the PK of antituberculosis drugs in diabetic individuals to provide in-depth analysis to guide patient management.

METHODS

Search Strategy

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We retrieved all original studies evaluating the effect of DM on the PK of all TB drugs recommended by the WHO for the treatment of drug-sensitive (DS) and drug-resistant TB. We systematically searched major databases including conference abstracts from 1946 to 6th of July 2023 using Medical Subject Headings (MeSH) terms (Supplementary Material). We also manually screened the references of included original studies. To identify unpublished studies, http://clinicaltrials.gov was searched. This systematic review was conducted in accordance with the PRISMA statement. The protocol was registered at PROSPERO (CRD42022323566).

Study Selection

Studies that reported PK of anti-TB medications among DM and non-DM participants were included. No restrictions on language and publication date were applied. General PK studies reporting a subgroup of DM participants were not eligible unless they included detailed PK parameters for DM and non-DM participants. Review articles, letters, case reports and case series with less than five participants were excluded, as were non-human studies.

Data Extraction

Two authors screened and retrieved articles according to the eligibility criteria and performed full text review and final article selection. The following variables were extracted: demographics of comparator group(s) and the DM group including age, weight, and sex, study design, DM diagnosis, and DM medications, dose, dosing interval, sampling points, AUC, peak drug concentration (C_{max}), half-life (t½), time to reach C_{max} (T_{max}), volume of distribution (Vd) and clearance (CL) and were stratified by group. If these data were not reported, we also contacted the authors to request the data.

Risk of bias in included studies

In the absence of available tools to assess risk of bias in PK studies, we assessed study quality and risk of bias using the ROBINS-I tool for non-randomised studies of interventions.[14] Any disagreements regarding grading of quality were resolved through discussion with a third author.

Analysis

Narrative synthesis of the findings was conducted and reported according to the Synthesis Without Meta-analysis (SWiM) guidelines. Descriptive statistics was used to describe key

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

outcome measures. The pooled mean difference (MD) and 95% confidence interval (CI) was calculated for the main PK parameters of RIF, INH, PZA and ethambutol (ETB), through a random-effects model, when at least data from two studies were available. We compared values between TB patients with and without DM. Data expressed as medians (with interquartile range, IQR) were converted to means and standard deviations (SD).[15] The pooling was performed according to an available case analysis scenario. Studies reporting means without SD values, medians without enough data to derive means and those reporting geometric means were excluded, since arithmetic means cannot be computed without raw data and log-transformed data cannot be mixed with untransformed ones in a meta-analysis.[16] To express the amount of heterogeneity and estimate the between-study variance, when at least three studies were available for pooling a prediction interval (PI), was calculated.[17] All calculations were carried out using R software, version 4.1.0, 'meta' package.

RESULTS

4173 potentially relevant articles were identified. After removing duplicates, 3464 articles were retrieved for initial screening and 49 studies were included for full text review. After reviewing the eligibility criteria, 21 articles were included that assessed the PK of anti-TB medications among TB-DM patients. [11,18-37] Five included papers presented the same data: in conference abstract [38-42] and then in published form; [19,25,29,32,39] we included data from the published report. One study was only published as a conference abstract and the authors were not able to share data at the time of this review. [43] No relevant unpublished studies were found. The study selection process is recorded in a PRISMA flow diagram (**Figure 1**).

Risk of bias assessment

The risk of bias for each domain across all included studies is given in Supplementary material. While all studies have made a comparative analysis between DM and non-DM population, all had moderate to serious risk of bias in at least one domain. Overall, the existing body of literature examining PK of anti-TB medications among DM population is of medium quality.

Rifampicin (Table 1)

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Of the 21 studies, 16 measured RIF plasma concentrations, [11,18,19,21,23,24,26-32,34-36] majority of which were prospective PK studies except one retrospective study reporting results based on routinely collected data. [24]

Out of 16 studies, 7 reported AUC values; three with intensive sampling (> 6 samples) [27,28,34] reporting AUC_{0-24} mg.h/L, three reported AUC_{0-6} mg.h/L, [11,29,32] and one reported AUC_{0-8} mg.h/L.[23] Fifteen measured RIF peak concentrations (C_{max}); mean absolute RIF C_{max} was below the recommended range (above 8 mg/L [44]) in diabetic and non-diabetic groups in the majority of studies, and within the recommended range only in the 3 studies with intensive sampling. [27,28,34] Eight studies measured T_{max}. In a study using population PK modelling, absorption rate constant (ka) was significantly increased and the volume of distribution (Vd) was significantly increased in the DM, [19] the authors inferring that the plasma concentrations would therefore be lower in the DM group. Another study found no difference in ka or Vd between the TB and TB-DM groups, but reduced clearance was observed and Vd was significantly higher in the TB-DM group when Vd was normalized to total body weight. [27]

Raised blood glucose was inversely correlated with the rifampicin AUC/C_{max} in four studies, [27,29,35,36] whereas three other studies found no association.[21,28,34] Two studies found that body weight and plasma concentrations were inversely correlated. [18,29]

There were significant differences between DM and non-DM groups. Nine studies reported that DM patients had significantly higher BMI or weight [11,18,21,23,26,27,29,32,35] and nine studies reported the DM group to be older [11,18,26-28,30,32,34,36]. One study that matched based on sex and age found C_{max} and AUC to be significantly lower and T_{max} significantly longer among DM group compared to non-DM. Eight studies reported DM patients to be on diabetes treatment [11,18,21,26-30,36], although no comparative analysis could be done as the majority of patients were receiving anti-diabetic medications.

Methodology differed between studies. Of the five studies finding a significantly decreased C_{max} in the diabetic group, four performed only a single 2-hour sampling [18,24,35,36], with one retrospective study [24] and one likely confounded by differences in weight (DM patients weighing more) [29].

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

DM patients had higher weight and/or BMI and some studies demonstrated a negative association between weight and plasma concentrations. The only study that matched based on weight (within 5 kg) [34] found no significant difference of RIF PK between groups. RIF doses used highly differed between studies which may have influenced the results, doses used detailed in Table 1.

Isoniazid (Table 1)

Nine studies assessed isoniazid (INH) PK. [11,18,22-24,26,28,31,33] Of these, one was based on routinely collected retrospective data, [24] four studies used 600 mg dosing 3 times per week [11,23,26,31] and only 1 study sampled intensively. [28] Four studies assessed for NAT2 status using different methods. [22,23,28,33]

Out of nine studies, four assessed the mean exposure; one AUC_{0-24} mg.h/L, [28] two AUC_{0-6} mg.h/L [11,33] and one AUC_{0-8} mg.h/L. [23] Four studies examined INH C_{max} [11,18,26,28] and three studies assessed T_{max}. [23,33]

While one study reported concentrations to be negatively correlated with blood glucose, [26] in two studies INH C_{max}/AUC was not correlated with FBG or HbA1c. [22,28] In one study INH concentrations were inversely correlated with weight. [18] There were significant differences between groups with the DM group being older and weighing more than non-DM group.

Pyrazinamide (Table 1)

Pyrazinamide PK was reviewed in eight studies, [11,18,23,25,26,28,31,34] all of which were prospective PK studies. Patients in all studies except two were on 1500 mg PZA dosing, whilst one study used 1600 mg for patients >50 kg and 1200 mg for patients <50 kg [28] and other used 20-30 mg/kg. [25] Out of eight, four papers reported mean exposure to PZA; two reporting AUC_{0-24} mg.h/L, [28,34] one AUC_{0-8} mg.h/L [23] and one AUC_{0-6} mg.h/L. [11] Six studies reported C_{max} and three studies measured T_{max}.

No correlation between FBG and AUC/C_{max} was observed in two studies [28,34] whereas one study showed a negative correlation.[26] In a population PK modelling study, [25] increased apparent clearance was observed in TB-DM patients, most significantly in the group with patients >70 years and AUC_{0-24} mg.h/L was decreased in the DM group >70 years.

Ethambutol (Table 1)

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Three included studies assessed the effect of DM on EMB PK. [18,28,34] Two reported AUC_{0-24} mg.h/L and T_{max} [28,34], all reported C_{max}.

Other agents (Table 1)

Two studies assessed the effect of DM on cycloserine, [37] linezolid [37] and moxifloxacin. [20] A retrospective cross-sectional study reviewing the 2 h post-dose in routine practice found that 55% of the samples had below the lower limit of recommended cycloserine plasma concentrations and 17% had low linezolid concentrations. [37] DM patients had a lower cycloserine exposure, although this was not statistically significant, and there was no association between linezolid exposure and DM. In a recent retrospective study evaluating moxifloxacin PK, $AUC_{0–24h}$ was shown to be significantly lower in patients with DM compared to age, sex and RIF matched TB patients without DM. [20] In line, peak and trough concentrations were also reduced in DM patients. Although the drug absorption, volume of distribution and T_{max} were comparable between TB-DM and TB patients, moxifloxacin clearance was increased in TB-DM patients.

Meta-analysis

A quantitative pooling was possible in seven cases, of which four involved RIF. We pooled data from four studies reporting RIF T_{max}.[27-30,34] Overall, RIF T_{max} was significantly higher in the TB-DM group: MD 0.65 (95% CI, 0.03-1.27) (Figure 2). Two studies were pooled for RIF AUC_{0-24},[27,30] four for RIF C_{max} [21,23,27,30] and four for RIF C_{2hr} [18,26,31,35], and no statistically significant differences were detected (Figure 2-3). However, RIF C_{2hr} was lower in TB-DM group with a MD of -1.68 (95% CI, -5.41; 2.05). In regard to other first line drugs, we observed no significant differences for INH C2hr, PZA C2hr, PZA T_{max} and ETB T_{max} (supplementary material).

DISCUSSION

This systematic review provides a comprehensive account of the impact of DM on the PK of anti-TB medications. While the evidence is heterogeneious, according to our analysis, RIF T_{max} is significantly prolonged in patients with DM compared to non-DM patients; however, PI crossed the no-effect threshold, indicating that in future studies opposite results may be determined. Whereas we found no significant differences between DM and non-DM patients for RIF C_{max}, AUC $_{0-24}$ or C2hr, INH C2hr, PZA C2hr, PZA T_{max} and ETB

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

T_{max}. While RIF C2hr was slightly reduced in TB-DM patients, this finding was not statistically significant.

Diabetes predominantly effects gastric motility via neuropathy.[12] This would be postulated to prolong T_{max} rather than reduce the overall AUC. Our findings of prolonged RIF T_{max} may be a reflection of the impact of DM on gastric motility and delay in drug absorption. However, the efficacy of most of the anti-TB medications is driven by AUC, which is difficult to determine with 1 or 2 sampling timepoints. Therefore, interpretation of studies with limited sampling points should be with caution. Studies with more than one sampling point, ideally with intensive sampling comparing DM vs non-DM population, or limited sampling strategy using population PK modelling will guide our management strategy in this population.

There is some evidence that PK among DM patients, may have clinical relevance in terms of MIC and culture conversion. In a retrospective study, where all DM patients underwent TDM and dose adjustment accordingly, time to culture conversion improved significantly (average 19 days earlier) among DM patients. [45] Recently, studies with higher doses of RIF has demonstrated bacteriologically sustained cure in a general TB population.[46] Perhaps these results and the higher RIF strategy have more relevance for the TB-DM population in which we observe more heterogenous plasma concentrations and that reducing the bacterial burden quicker may result in reduced relapse rates.

We observed high variability in findings and significant heterogeneity among studies. Firstly, there were differences in terms of demographics; age, sex and body weight, DM diagnosis and anti-DM medications. Increased body surface area distribution, delayed drug absorption due to DM related gastroparesis and changes in expression of enzymes involved in metabolism [47] are major factors that may contribute to altered PK. [12,48] In most studies, DM patients weighted more than non-DM controls. However, matching weight is unlikely to eliminate potential biases as DM participants continued to receive capped dosing despite weight differences. Screenning DM at the time of TB diagnosis may result in some with transient hyperglycaemia being identified as DM. While most of the patients were on anti-diabetic medications, the degree of diabetic control was not provided, limiting our understanding.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Secondly, PK sampling methodology and drug doses used varied widely across studies. Those with a single 2 hr sampling point assume T_{max} to occur at 2 hrs (C_{max}). Therefore, studies without intensive sampling may not accurately capture the C_{max}. However, it is important to note T_{max} is highly variable for RIF in general. Particularly affecting the isoniazid studies, dosing differed markedly, with 4 out of 9 using 600 mg 3 times/week, which is no longer recommended. Only four out of 9 studies made any assessment of NAT2 acetylator status which is a key variable in isoniazid PK likely to confound results. [49]

We identified another systematic review assessing the impact of DM on the PK of rifampicin among TB patients [50]. The review included studies published up until September 2020 and identified seven studies from which pooled estimates were calculated. The same authors updated their systematic review including studies with C_{max} at 2hr, [51] and identified 17 studies reporting RIF plasma concentrations.

Our study has limitations. Firstly, we identified a limited number of PK studies despite a comprehensive literature search. Secondly, due to studies reporting geometric means we were unable to pool data from those reporting AUC 0-24. Finally, we did not include general PK studies reporting on TB-DM patients as a subgroup.

Given the association observed between dose adjustment and clinical improvement, dose adjustment based on TDM may be beneficial in this patient population. We recognise that in most global settings TDM is not easily available. Until more simplified and cost-effective tests are easily available, [52] the alternative would be to empirically increase drug doses in all individuals with DM. While TB drug exposures in diabetes is mixed, given RIF has a wide therapeutic window [53] and successful treatment outcome depends on sufficient drug exposure, we recommend considering a higher dose limit for patients with DM; instead of capped dosing, using 10mg/kg to be able to correct for larger bodyweight of patients with DM. This is also a group that should be prioritised in ongoing studies addressing empirically increasing doses of TB medications. In order to achieve definitive answers for PK in DM population, we recommend important considerations as in **Table 2**.

Acknowledgements

This work was supported by the Chief Scientist Office (CAF/20/03) and British Infection Association (Grant/2022/SPG/MC) received by MC.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Author contributions

MC conceptualized the scope of the review, led the systematic review, literature search, data collection and wrote the first and subsequent drafts of the manuscript. AS involved in creating the table from selected papers. AEM performed the meta-analysis on selected papers. All authors contributed to the final version of the manuscript and approved it for publication.

Declaration of Interests

No conflict of interests reported.

Figures and tables:

Figure 1: Flowchart describing study selection

Figure 2: Meta-analysis of Rifampicin (RIF AUC0-24 and RIF Tmax)

Figure 3: Meta-analysis of Rifampicin (RIF Cmax and C2hr)

Table 1: Summary of included studies

Table 2: Recommendations for future research

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References:

1. WHO. World Health Organization, Global tuberculosis report 2022 . 2022. https://www.who.int/publications/i/item/9789240061729.
2. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018; **138**: 271-81.
3. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. *Lancet Glob Health* 2019; **7**(4): e448-e60.
4. Koesoemadinata RC, McAllister SM, Soetedjo NNM, et al. Latent TB infection and pulmonary TB disease among patients with diabetes mellitus in Bandung, Indonesia. *Trans R Soc Trop Med Hyg* 2017; **111**(2): 81-9.
5. Foe-Essomba JR, Kenmoe S, Tchatchouang S, et al. Diabetes mellitus and tuberculosis, a systematic review and meta-analysis with sensitivity analysis for studies comparable for confounders. *PLoS One* 2021; **16**(12): e0261246.
6. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med* 2011; **9**: 81.
7. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *Int J Tuberc Lung Dis* 2019; **23**(7): 783-96.
8. Dong Z, Shi J, Dorhoi A, et al. Hemostasis and Lipoprotein Indices Signify Exacerbated Lung Injury in TB With Diabetes Comorbidity. *Chest* 2018; **153**(5): 1187-200.
9. Salindri AD, Kipiani M, Kempker RR, et al. Diabetes Reduces the Rate of Sputum Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis. *Open Forum Infect Dis* 2016; **3**(3): ofw126.
10. Zheng X, Bao Z, Forsman LD, et al. Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. *Clin Infect Dis* 2021; **73**(9): e3520-e8.
11. Alfarisi O, Mave V, Gaikwad S, et al. Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment. *Antimicrob Agents Chemother* 2018; **62**(11): 11.
12. Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. *Clin Pharmacokinet* 2012; **51**(8): 481-99.
13. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. *Antimicrob Agents Chemother* 2002; **46**(2): 267-74.
14. Gafar F, Wasmann RE, McIlleron HM, et al. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. *Eur Respir J* 2023; **61**(3).
15. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014; **14**: 135.
16. Deeks JJ HJ, Altman DG Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. .
17. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ* 2011; **342**: d549.
18. Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. *Antimicrob Agents Chemother* 2013; **57**(11): 5740-2.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

19. Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. *Tuberculosis (Edinb)* 2015; **95**(1): 54-9.
20. Dekkers BGJ, Bolhuis MS, Beek LT, et al. Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. *European Respiratory Journal* 2019; **54(3) (no pagination)**.
21. Fonseca AAD, Pinto ACG, Paixao TPD, Alberio CAA, Vieira JLF. Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis? *Brazilian Journal of Infectious Diseases* 2020; **24(4)**: 352-5.
22. Galvao FES, Fonseca AAD, Pinto ACG, da Paixao TP, Alberio CAA, Vieira JLF. No significant influence of diabetic mellitus on isoniazid plasma levels in patients under treatment for tuberculosis. *Infectious Diseases* 2020; **52(8)**: 577-80.
23. Hemanth Kumar AK, Kannan T, Chandrasekaran V, et al. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. *Int J Tuberc Lung Dis* 2016; **20**(9): 1236-41.
24. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. *Emerg Infect Dis* 2010; **16**(10): 1546-53.
25. Kim R, Jayanti RP, Kim HK, et al. Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance. *Front Pharmacol* 2023; **14 (no pagination)**: 1116226.
26. Kumar AK, Chandrasekaran V, Kannan T, et al. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus. *Eur J Clin Pharmacol* 2017; **73**(1): 65-70.
27. Medellin-Garibay SE, Cortez-Espinosa N, Milan-Segovia RC, et al. Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters. *Antimicrob Agents Chemother* 2015; **59**(12): 7707-14.
28. Mtabho CM, Semvua HH, van den Boogaard J, et al. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. *J Antimicrob Chemother* 2019; **74**(12): 3537-45.
29. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. *Clin Infect Dis* 2006; **43**(7): 848-54.
30. Perea-Jacobo R, Muniz-Salazar R, Laniado-Laborin R, Cabello-Pasini A, Zenteno-Cuevas R, Ochoa-Teran A. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico. *Int J Tuberc Lung Dis* 2019; **23**(9): 1012-6.
31. Ramachandran G, Chandrasekaran P, Gaikwad S, et al. Subtherapeutic rifampicin concentration is associated with unfavorable tuberculosis treatment outcomes. *Clin Infect Dis* 2020; **70(7)**: 1463-70.
32. Requena-Mendez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. *Antimicrob Agents Chemother* 2012; **56**(5): 2357-63.
33. Requena-Mendez A, Davies G, Waterhouse D, et al. Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. *Antimicrob Agents Chemother* 2014; **58**(12): 7164-70.
34. Ruslami R, Nijland HM, Adhiarta IG, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. *Antimicrob Agents Chemother* 2010; **54**(3): 1068-74.
35. Samuel Gideon George P, Saranya P. Effect of patient-specific variables on rifampicin peak serum concentration. *Drug Invention Today* 2018; **10(3)**: 290-6.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

36. Saranya P, Parthasarathy V, Hariprasad B, Shobha Rani H. Effect of diabetes mellitus on rifampicin peak serum concentration. *International Journal of Pharmacy and Pharmaceutical Sciences* 2016; **8(10)**: 149-52.

37. Zhu H, Guo SC, Liu ZQ, et al. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China. *Int J Tuberc Lung Dis* 2018; **22**(8): 931-6.

38. Chang MJ, Shin W, Song J, et al. The pharmacokinetics of four standard anti-tuberculosis drugs in tuberculosis patients with diabetes mellitus. *Respirology* 2009; **3)**: A231.

39. Mtabho C, Semvua H, Kibiki G, Tostmann A, Aarnoutse R. The effect of diabetes mellitus on the pharmacokinetics of tuberculosis drugs in Tanzanian patients. *Tropical Medicine and International Health* 2015; **1)**: 23.

40. Nijland H, Ruslami R, Stalenhoef J, et al. Exposure to rifampicin is reduced by 53% in tuberculosis patients with Diabetes Mellitus. *Br J Clin Pharmacol* 2006; **62**(6): 730-.

41. Mendez AR, Moore DAJ, Davies G. Improving management of TB in the tropics Rifampicin pharmacokinetics in peruvian tuberculosis patients with and without co-morbid diabetes or HIV. *Tropical Medicine and International Health* 2011; **1)**: 62.

42. Kim R, Jayanti R, Jang T, et al. Development of Population Pharm Aco Kin Etics Model of Pyrazinamide and Optimal Dose Recommendation for Elderly with Diabetes Mellitus in Korean Tuberculosis Patients. *Clinical Pharmacology and Therapeutics* 2023; **113(Supplement 1)**(S1): S94.

43. Christopher DJ, Jedidiah D, Isaac B, Mathew B, Winston B. Anti-tubercular drug concentrations in pulmonary tuberculosis patients-diabetic vs non-diabetic groups. *European Respiratory Journal Conference: 29th International Congress of the European Respiratory Society, ERS Madrid Spain* 2019; **54**(Supplement 63).

44. Peloquin CA, Velasquez GE, Lecca L, et al. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. *Antimicrob Agents Chemother* 2017; **61**(8).

45. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. *BMC Infect Dis* 2017; **17**(1): 125.

46. Paton NI, Cousins C, Suresh C, et al. Treatment Strategy for Rifampin-Susceptible Tuberculosis. *N Engl J Med* 2023; **388**(10): 873-87.

47. Kuppusamy UR, Indran M, Rokiah P. Glycaemic control in relation to xanthine oxidase and antioxidant indices in Malaysian Type 2 diabetes patients. *Diabet Med* 2005; **22**(10): 1343-6.

48. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. *Clin Pharmacokinet* 1991; **20**(6): 477-90.

49. Hong BL, D'Cunha R, Li P, et al. A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis. *Clin Ther* 2020; **42**(11): e220-e41.

50. Metwally AS, El-Sheikh SMA, Galal AAA. The impact of diabetes mellitus on the pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-analysis study. *Diabetes Metab Syndr* 2022; **16**(2): 102410.

51. El-Sheikh SMA, Metwally AS, Galal AAA. Impact of diabetes mellitus on rifampicin's plasma concentration and bioavailability in patients with tuberculosis: A systematic review and meta-analysis study. *Therapie* 2023; **78**(3): 313-24.

52. Xie YL, Modi N, Handler D, et al. Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study. *Antimicrob Agents Chemother* 2023; **67**(11): e0093223.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

53. Akkerman OW, Dijkwel RDC, Kerstjens HAM, et al. Isoniazid and rifampicin exposure during treatment in drug-susceptible TB. *Int J Tuberc Lung Dis* 2023; **27**(10): 772-7.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.29.23294656; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1. Flowchart describing study selection



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *P*referred *R*eporting *I*tems for *S*ystematic Reviews and *M*eta-*A*nalyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.